One may also envisage arming OVs with intrabodies (intracellular antibodies), inhibitory short hairpin RNAs (shRNAs) or ribozyme switches targeting cancer cell surface co-inhibitory molecules such as PD-L1, B7-H, CD47 (inhibiting phagocytosis by macrophages) or other inhibitory ligands. This evidence concerns the gene CD274 and cancer.